News Sentiment

IMM sentiment intelligence

Immutep Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed

Weighted score 53 Balanced news tone 27 relevant articles

Exchange ASX Australia

Sector Healthcare Market context

Industry Biotechnology Read-through group

Latest close 0.05 Week of 10 Jul 2026

Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

90/100 classification confidence.

Company focus 27

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-7.3% over one week, +8.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Immutep Shares Rocket Nearly 15% as Immunotherapy Momentum Returns to the ASX

Market Reaction

Price moving ahead of tone

65/100 confidence

Primary event Market update 90/100 classification

One-week reaction -7.3% Price reacting lower

Trend fit Trend inactive 8.5% over four weeks

Fair value -82.6% Below fair value

Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance

Positive 4

Neutral 23

Negative 0

Relevance

Why the article matched

Direct first

Direct company coverage 27

Industry context 0

Sector context 0

Sources

Coverage mix

Publishers

Kalkine 5

simplywall.st 5

Market source 3

Stocks Down Under 2

BioWorld News 2

Stockhead 1

Kalkine Media 1

Stock Titan 1

Event Lens

What the news is about

Classified themes

Market update 23

Deals and strategy 2

Balance sheet 1

Earnings 1

Sentiment Trail

Score over time

50 baseline

Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-27 of 27

Kalkine Direct company coverage

Immutep Shares Rocket Nearly 15% as Immunotherapy Momentum Returns to the ASX

Tone: Neutral 50/100
Event: Market update
Published: 13 Jul 2026 08:19
Source: Kalkine

Kalkine Direct company coverage

Why Did Immutep (ASX: IMM) Jump 13.73%?

Tone: Neutral 50/100
Event: Market update
Published: 13 Jul 2026 06:32
Source: Kalkine

Kalkine Direct company coverage

Immutep (ASX:IMM) Shares Surge Nearly 14% as Healthcare Momentum Grabs the ASX Spotlight

Tone: Positive 66/100
Event: Market update
Published: 13 Jul 2026 04:30
Source: Kalkine

Stockhead Direct company coverage

Health Check: Immutep shares bounce on revived lung cancer treatment hopes

Tone: Neutral 50/100
Event: Market update
Published: 13 Jul 2026 02:38
Source: Stockhead

Stocks Down Under Direct company coverage

Immutep (ASX:IMM) posts 30.9-month survival as TACTI-004 forensics finally get interesting

Tone: Neutral 50/100
Event: Market update
Published: 13 Jul 2026 00:41
Source: Stocks Down Under

Kalkine Media Direct company coverage

Immutep (ASX:IMM): Why These ASX Penny Stocks Are Drawing Attention

Tone: Neutral 50/100
Event: Market update
Published: 24 Jun 2026 07:00
Source: Kalkine Media

simplywall.st Direct company coverage

ASX Penny Stocks: Immutep And Two More Companies To Watch

Tone: Neutral 50/100
Event: Market update
Published: 23 Jun 2026 07:00
Source: simplywall.st

simplywall.st Direct company coverage

Here's Why We're Watching Immutep's (ASX:IMM) Cash Burn Situation

Tone: Neutral 50/100
Event: Balance sheet
Published: 19 Jun 2026 07:00
Source: simplywall.st

Market source Direct company coverage

Is Immutep (ASX:IMM) In A Good Position To Deliver On Growth Plans?

Tone: Positive 66/100
Event: Market update
Published: 10 May 2026 07:00
Source: Market source

Stock Titan Direct company coverage

Immutep (IMMP) director details Ordinary Shares and performance rights

Tone: Neutral 50/100
Event: Market update
Published: 16 Apr 2026 07:00
Source: Stock Titan

Stocks Down Under Direct company coverage

Immutep (ASX:IMM) wins FDA orphan status as efti Phase 2 hits 51.5% endpoint

Tone: Neutral 50/100
Event: Market update
Published: 15 Apr 2026 07:00
Source: Stocks Down Under

SMH.com.au Direct company coverage

ASX Runners of the Week: Immutep, Blue Star Helium & Patagonia

Tone: Neutral 50/100
Event: Market update
Published: 20 Mar 2026 07:00
Source: SMH.com.au

BioWorld News Direct company coverage

Immutep stock plummets 90% on efti phase III failure in NSCLC

Tone: Neutral 50/100
Event: Market update
Published: 17 Mar 2026 07:00
Source: BioWorld News

Kalkine Direct company coverage

Immutep (ASX:IMM) Stock Surges 42% as Biotech Pipeline Attracts Investor Interest

Tone: Positive 66/100
Event: Market update
Published: 16 Mar 2026 07:00
Source: Kalkine

Fierce Biotech Direct company coverage

Immutep's phase 3 failure for immunotherapy surprises analysts, sinks stock

Tone: Neutral 50/100
Event: Market update
Published: 13 Mar 2026 07:00
Source: Fierce Biotech

Proactive financial news Direct company coverage

Inside Biotech: Phase III setback sends Immutep shares into freefall

Tone: Neutral 50/100
Event: Market update
Published: 13 Mar 2026 07:00
Source: Proactive financial news

Market Index Direct company coverage

Immutep crashes 90% as Phase III lung cancer trial discontinued

Tone: Neutral 50/100
Event: Market update
Published: 13 Mar 2026 07:00
Source: Market Index

Investing.com Direct company coverage

Immutep stock plunges 80% after lung cancer trial halted

Tone: Neutral 50/100
Event: Market update
Published: 13 Mar 2026 07:00
Source: Investing.com

Kalkine Direct company coverage

Immutep (ASX:IMM) Stock Crashes 88.60% After Phase III Trial Failure: What Investors Need to Know

Tone: Neutral 50/100
Event: Market update
Published: 13 Mar 2026 07:00
Source: Kalkine

The Motley Fool Australia Direct company coverage

Why the Immutep share price is halted today

Tone: Neutral 50/100
Event: Market update
Published: 09 Mar 2026 07:00
Source: The Motley Fool Australia

simplywall.st Direct company coverage

Immutep H1 2026 Loss Worsening Challenges Bullish Revenue Growth Narratives

Tone: Positive 66/100
Event: Earnings
Published: 26 Feb 2026 08:00
Source: simplywall.st

Market source Direct company coverage

Immutep Limited (ASX:IMM) is largely controlled by institutional shareholders who own 50% of the company

Tone: Neutral 50/100
Event: Market update
Published: 09 Feb 2026 08:00
Source: Market source

simplywall.st Direct company coverage

ASX Penny Stocks Spotlight: Immutep And Two More To Consider

Tone: Neutral 50/100
Event: Market update
Published: 13 Jan 2026 08:00
Source: simplywall.st

simplywall.st Direct company coverage

Immutep (ASX:IMM): Valuation Check After Dr. Reddy’s Licensing Deal and New Phase II Breast Cancer Data

Tone: Neutral 50/100
Event: Deals and strategy
Published: 10 Dec 2025 08:00
Source: simplywall.st

BioWorld News Direct company coverage

Immutep shares rocket on AU$528M deal with Dr. Reddy’s

Tone: Neutral 50/100
Event: Deals and strategy
Published: 09 Dec 2025 08:00
Source: BioWorld News

Market source Direct company coverage

ASX Penny Stock Highlights: Immutep And 2 Other Noteworthy Picks

Tone: Neutral 50/100
Event: Market update
Published: 16 Nov 2025 08:00
Source: Market source

smallcaps.com.au Direct company coverage

Insights: Immutep Ltd (ASX:IMM)

Tone: Neutral 50/100
Event: Market update
Published: 30 Oct 2025 10:32
Source: smallcaps.com.au